And no one is more ready to make it happen than Sanofi CEO Paul Hudson. Last week, Hudson proudly announced his company’s new ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical trials.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

Sanofi could be "bit more" active with M&A in ... R&D spending has increased as CEO Paul Hudson looks to boost clinical trials for next-generation drugs. His spending plans were initially met ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...